https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Achieving the World Health Organization's vision for clinical pharmacology https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28081 Wed 11 Apr 2018 13:03:57 AEST ]]> Expert advice for prescribing cannabis medicines for patients with epilepsy—drawn from the Australian clinical experience https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48538 Tue 21 Mar 2023 15:23:57 AEDT ]]> Unique approach to continuing medical education in clinical pharmacology across Australia and New Zealand https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37568 Thu 18 Feb 2021 16:08:21 AEDT ]]> Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New Zealand https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52234 Thu 05 Oct 2023 11:39:44 AEDT ]]> Clinical pharmacology in research, teaching and health care https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10546 Sat 24 Mar 2018 08:10:20 AEDT ]]> An agenda for UK clinical pharmacology: An Australian perspective https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17339 Sat 24 Mar 2018 08:01:41 AEDT ]]> Population pharmacokinetic-pharmacodynamic modelling to describe the effects of paracetamol and N-acetylcysteine on the international normalized ratio https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27173 Sat 24 Mar 2018 07:31:43 AEDT ]]> Complementary and alternative therapies in the palliative setting https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51100 Mon 21 Aug 2023 15:06:10 AEST ]]> Why maximum tolerated dose? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37136 start low and go slow. However, clinicians often prescribe up to maximum tolerated dose (MTD), especially when treating acute and more severe disease, without evidence to show that MTD is more likely to improve outcomes. Cardiovascular guidelines for some indications advocate MTD even in prevention, for example hypercholesterolaemia, without compelling evidence of better outcomes. This review explores the origins and potential problems of prescribing medications at MTD. Oral effective dose 50 (ED50) may be a useful guide for balancing efficacy and safety.]]> Mon 14 Nov 2022 19:04:49 AEDT ]]> The valley of death: why Australia failed to develop clinically effective drugs in COVID-19 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54959 Fri 22 Mar 2024 15:34:59 AEDT ]]>